Summary & Overview
HCPCS J1080: Testosterone Cypionate Injection, 200 mg
HCPCS Level II code J1080 identifies a 1 cc (200 mg) injection of testosterone cypionate, an intramuscular formulation used primarily for testosterone replacement therapy. This code matters nationally because testosterone injections are commonly used across adult medicine, endocrinology, and urology, and injectable drug codes drive coverage, prior authorization, and reimbursement processes for outpatient care.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for testosterone cypionate, typical sites of service for administration, and the role of HCPCS coding in billing for drug administration in outpatient settings. The publication summarizes benchmark topics commonly analyzed for J-codes—coverage patterns, prior authorization tendencies, and reimbursement frameworks—while noting where specific payer policies influence access and billing workflows.
This summary provides national-level context for clinicians, practice managers, and billing staff seeking a concise reference to code purpose and the types of policy considerations they should expect when billing for testosterone cypionate injections. Data not available in the input for payor-specific rates, modifier usage, taxonomies, ICD-10 pairings, and related codes is clearly indicated for readers seeking deeper operational detail.
Billing Code Overview
HCPCS Level II code J1080 describes an injection of testosterone cypionate, supplied as 1 cc (200 mg). The service type is injectable medication administration intended for testosterone replacement therapy. The typical site of service is outpatient settings including physician offices, clinics, and ambulatory care centers where intramuscular injections are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult male with hypogonadism who presents to an outpatient clinic for ongoing testosterone replacement therapy. The clinician prescribes intramuscular J1080 (testosterone cypionate, 200 mg per 1 cc) to be administered every 1–2 weeks depending on dosing regimen and serum testosterone levels. The clinical workflow includes: initial evaluation (history, physical exam, baseline laboratory tests including morning serum total testosterone, LH, FSH, CBC, PSA for appropriate age/risks), informed discussion of risks and benefits, medication order entry for J1080, verification of allergy and consent, preparation of the intramuscular dose by nursing, and administration (typically into the gluteal or deltoid muscle) with documentation of lot number, dose, site, and patient tolerance. Follow-up visits include interval symptom review, monitoring of testosterone levels, hematocrit, and prostate-specific antigen when indicated. Typical sites of service are outpatient clinic, ambulatory infusion center, or physician office.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M is documented and distinct from the injection visit |